Literature DB >> 11230990

Receptor polymorphisms and diseases.

A Császár1, T Abel.   

Abstract

The aim of our review is to summarize common genetic variations of some receptors associated with clinical consequences, which were not outlined in the previous special issue of this journal. Because of the multiple pathomechanisms of diseases, a set of genetic variation can play a role in the development of pathological conditions. From the data available three articles would merit a greater interest. In systemic lupus erythematosus the associations related to some polymorphisms of Fc-, tumor necrosis factor (TNF) alpha- and interferon receptor may explore new autoimmunological and inflammatorical pathomechanisms. In the endocrinology, the androgen receptor repeat polymorphism will exert significant aspects in the development of prostate cancer. The pleoitropic responsibility of vitamin D3 receptor polymorphism in the pathogenesis of immunological disorders (primary biliary cirrhosis, inflammatory bowel disease, type 1 diabetes mellitus) and of malignancies (malignant melanoma, breast cancer) shed light on the importance of common nuclear receptors. Nevertheless, in the future studies a more consistent approach minimizing requirement bias in the selection of patients will approve our understanding the role of genetic influence on the pathogenesis of diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11230990     DOI: 10.1016/s0014-2999(01)00755-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Vitamin D receptor FokI, TaqI, and ApaI polymorphisms and susceptibility to systemic lupus erythematosus: an updated meta-analysis.

Authors:  Sang-Cheol Bae; Young Ho Lee
Journal:  Clin Rheumatol       Date:  2018-02-21       Impact factor: 2.980

2.  A Golgi-localized hexose transporter is involved in heterotrimeric G protein-mediated early development in Arabidopsis.

Authors:  Helen X Wang; Ravisha R Weerasinghe; Tony D Perdue; Nihal G Cakmakci; J Philip Taylor; William F Marzluff; Alan M Jones
Journal:  Mol Biol Cell       Date:  2006-07-19       Impact factor: 4.138

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.